Mary Kay Inc., via its Mary Kay Ash Basis, is supporting a groundbreaking initiative that goals to revolutionize early detection and intervention methods for breast most cancers. The inspiration’s beneficiant grant is funding the TRIM-EBC Trial (Tirzepatide weight reduction in sufferers with MRD and Early Breast Most cancers) in alignment with Baylor Scott & White Well being and the Texas Most cancers Interception Institute (TCII). Led by Joyce O’Shaughnessy, MD, the research investigates whether or not weight reduction via tirzepatide may scale back breast most cancers incidence by reducing or eliminating circulating tumor DNA.
The Mary Kay Ash Basis’s donations to those efforts are a part of its long-term dedication to advance the vital work of lowering the danger of breast most cancers and discovering cures for cancers affecting ladies, and displays its dedication to shaping the way forward for most cancers interception and prevention methods.
Dr. O’Shaughnessy is a key participant within the TRIM-EBC Trial and was honored as one of many nation’s main breast oncologists on the 2025 Celebrating Ladies Luncheon, the place the Mary Kay Ash Basis was additionally honored with the celebrated Circle of Care Award.
“Once I began greater than 35 years in the past, there have been no senior ladies school at my establishment – none,” Dr. O’Shaughnessy stated. “The alternatives simply weren’t there. That has modified dramatically. As soon as ladies started transferring into management roles and succeeding, it created a snowball impact. Seeing ladies in these positions makes others understand it’s attainable. That visibility is vital – not only for ladies generally, but additionally for minority ladies. You might want to see somebody like your self doing the job to consider you are able to do it too.”
